Drug
MEDI3506
MEDI3506 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
3
60%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
A Phase 2b Diabetic Kidney Disease Study
NCT04170543
completedphase_2
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
NCT04570657
completedphase_2
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
NCT04212169
completedphase_1
Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
NCT05070312
completedphase_1
Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
NCT03096795
Clinical Trials (5)
Showing 5 of 5 trials
NCT04170543Phase 2
A Phase 2b Diabetic Kidney Disease Study
NCT04570657Phase 2
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
NCT04212169Phase 2
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
NCT05070312Phase 1
Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
NCT03096795Phase 1
Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5